HUMANITAS MIRASOLE SPA

Steering Committee includes medical professionals from various hospitals across Argentina, Bolivia, Brazil, Chile, Colombia, Cuba, Ecuador, Mexico, Nicaragua, Paraguay, Uruguay, and Venezuela. Principal investigators are listed by country and hospital.

Greenwich LifeSciences partners with Italy's Gruppo Italiano Mammella (GIM) for Phase III FLAMINGO-01 trial evaluating GLSI-100 immunotherapy to prevent breast cancer recurrences. Nine top GIM institutions join the trial, with Italy being the first country to have all participating sites personally visited and trained by the company.